Health Policy and Advocacy

As the leading voice of independent urology group practices in the US, LUGPA educates policymakers on the benefits of integrated urologic care. Our members drive grassroots efforts by developing thoughtful analysis and engaging public officials through comment letters  on major legislative and regulatory proposals.



Recent Advocacy Updates and Policy Briefs:

See more policy updates from 2023-2025


Public Health Emergency Resources  
Public Health Emergency Ending May 2023
Read more. 


Elevate Your Practice: Why LUGPA Advocacy Matters

Discover the tools to shape the future of urology practice! Access our "LUGPA Advocacy: Why it Matters" materials for insights and resources to promote change. Let's amplify our voice and uphold autonomy in urology. You can learn more here.


TAKE ACTION:  Members of Congress Need to Hear from You!

     

When lawmakers hear directly from physicians in their own districts, they listen. At LUGPA, we know that your real-world experience is the most powerful tool in advocacy—putting a human face on the policy issues that affect independent urology every day.

  • Share your story—your way. Whether through a short video or a written testimonial, your perspective on reimbursement, administrative burden, patient access, workforce challenges, or practice sustainability helps policymakers understand the real impact of their decisions.

  • Join us in Washington, DC. Attend an in-person LUGPA fly-in and meet directly with lawmakers on Capitol Hill alongside the LUGPA Political Affairs Committee to advocate for independent urology. Contact us if to learn more.  

Your voice matters—and it can help shape meaningful change for our practices and our patients.
 


LUGPA’s 2027 Regulatory and Legislative Priorities

LUGPA is the national voice for independent urology practices. We advocate for a health-care system that preserves patient choice, supports physician-led care, and keeps high-quality specialty care accessible in communities nationwide.

Independent urology practices face persistent pressures from inadequate Medicare payment, rising practice costs, health-care consolidation, administrative burden, payer restrictions, and barriers to therapies and services.

LUGPA’s 2027 legislative agenda focuses on six priorities designed to strengthen independent practices, improve patient access, promote competition, and ensure that health-care policy recognizes the value of community-based, physician-led care.


Core Principles

Across these priorities, LUGPA emphasizes several core principles:

  • Patient Choice — Patients should be able to choose their physicians and receive appropriate specialty care close to home.
  • Physician-Led Care — Clinical decisions should remain grounded in the physician-patient relationship.
  • Competition — Health-care policy should promote competition rather than create financial incentives for unnecessary consolidation.
  • Appropriate Site of Care — Patients should receive care in the setting that is clinically appropriate, efficient, and aligned with their needs.
  • Practice Sustainability — Independent practices need a payment and regulatory environment that allows them to remain viable and continue investing in patient care.
  • Innovation — New technologies, treatments, and care models should be evaluated based on evidence and made accessible when they provide value to patients.

1. Advance Medicare Physician Payment Reform and Protect Independent Practice

Medicare physician payment remains LUGPA’s top legislative priority.

LUGPA supports comprehensive reform of the Medicare Physician Fee Schedule that delivers predictable, sustainable payment updates tied to the Medicare Economic Index (MEI) and accurately reflects the cost of operating a medical practice.

LUGPA will advocate for:

  • Establish predictable, annual Medicare physician payment updates tied to the Medicare Economic Index (MEI), with a mechanism to address persistent gaps between payment rates and the cost of operating a practice.
  • Modernize budget-neutrality rules by increasing the threshold for payment adjustments and periodically updating that threshold for inflation.
  • Require regular updates to practice-expense data, including clinical staff wages, medical supplies, equipment, and technology costs, and ensure that changes in practice expenses are reflected appropriately in physician payments.
  • Provide appropriate transition periods and safeguards against large, abrupt payment reductions when CMS revises service valuations or utilization assumptions.

Ongoing CMS payment rules continue to highlight these challenges, including conversion factor pressures and proposed changes to practice-expense and global-surgery methodologies that affect independent practices.

Why it matters: When Medicare payment fails to keep pace with the cost of care, independent practices face growing pressure to consolidate, reduce services, or change how and where they deliver care.

For urology practices, payment instability affects the ability to maintain office-based services, invest in diagnostic equipment, recruit clinical staff, and offer patients timely access to procedures and treatments close to home.

LUGPA’s goal: Build a Medicare payment system that keeps independent physicians financially viable so they can continue serving Medicare patients in their communities.


2. Promote Site-Neutral Payment and Community-Based Care

Medicare should not create financial incentives for consolidation.

LUGPA supports policies that align payment for comparable services based on the care provided—not the ownership of the facility.

LUGPA will advocate for:

  • Align Medicare payment for comparable services across hospital outpatient departments and physician-owned settings, accounting for legitimate differences in the resources required to deliver care.
  • Oppose reductions to payment for services billed with Modifier 25 that would penalize efficient, in-office care and discourage appropriate services during the same visit.
  • Require CMS to assess the impact of payment differentials on hospital acquisition of independent physician practices and the migration of services to higher-cost settings.
  • Protect access to urologic procedures in ambulatory surgery centers (ASCs) by regularly reviewing the ASC Covered Procedures List and expanding it when supported by clinical evidence and patient safety considerations.
  • Ensure that Medicare payment methodologies accurately recognize the practice expenses and resources required to provide care in physician offices and ASCs.

OPPS and ASC payment policies remain an important focus for advocacy as CMS continues to shape site-of-care incentives.

Why it matters: Payment disparities can encourage consolidation, raise costs, and reduce independent options available to patients.

Many urologic services, including cystoscopy, prostate biopsies, and selected surgical procedures, can be provided in physician offices or ASCs when clinically appropriate. Payment differences that favor hospital-owned settings can encourage consolidation, increase costs, and limit patients’ ability to receive care in their communities.

LUGPA’s goal: Ensure patients can receive appropriate urologic care in the most clinically appropriate setting without payment policy steering them toward hospital-owned facilities.


3. Protect Patient Access to Medications, Treatments, and Specialty Care

Patients should not lose access to appropriate treatment because of payment policies, utilization-management requirements, or changes in how therapies are reimbursed.

LUGPA will advocate for policies that:

  • Protect access to physician-administered drugs by evaluating how Medicare drug-pricing policies affect acquisition costs, reimbursement, and the ability of community practices to furnish treatment.
  • Ensure that Medicare reimbursement policies account for the costs and financial risks associated with acquiring and administering specialty medications.
  • Preserve independent urology practices’ ability to dispense and mail prescriptions to patients, consistent with applicable law and patient safety requirements.
  • Preserve patient access to medically appropriate treatment options, including radiologic therapies, injectable treatments, and other therapies furnished by urology practices.
  • Promote timely and transparent coverage decisions for new urologic treatments and technologies, with clear pathways for reconsideration as clinical evidence develops.

LUGPA will also continue working with health plans to address coverage policies that restrict access to appropriate urologic services and treatments, including policies that classify emerging technologies and procedures as experimental or investigational despite a growing body of clinical evidence.

Why it matters: Payment and coverage policies can determine whether patients can receive appropriate treatments from their existing physicians or are forced to change providers or settings.

Urologists provide a range of treatments for prostate and bladder cancer and other urologic conditions. For physician-administered therapies, reimbursement that does not adequately account for acquisition and administration costs can make it difficult for independent practices to continue offering treatment locally.

LUGPA’s goal: Patients should have access to appropriate treatments through the physician and setting that best meet their clinical needs.


4. Reduce Administrative Burden and Reform Prior Authorization

Physicians should spend their time treating patients—not navigating unnecessary administrative requirements.

LUGPA will advocate for meaningful reform of prior authorization, step therapy, and other utilization-management practices, including:

  • Establish enforceable deadlines for routine and urgent prior authorization decisions, with expedited review when delays could compromise patient care.
  • Support reforms that streamline prior authorization, establish enforceable decision timelines, impose consequences for unnecessary delays, and protect against repetitive authorization requirements that create administrative burdens and disrupt patient care.
  • Require payers to use standardized electronic processes, consistent clinical criteria, and clear explanations for denials.
  • Expand prior authorization exemptions for physicians and practices with demonstrated histories of appropriate utilization and adherence to evidence-based guidelines.
  • Prohibit avoidable reauthorization requirements for stable patients continuing an established treatment plan, subject to appropriate clinical safeguards.
  • Require advance notice and reasonable transition periods when health plans materially change coverage or utilization-management requirements.

LUGPA will also continue advocating for reforms that reduce the administrative and financial burden of collecting patient cost-sharing and meeting other payer requirements.

Why it matters: Administrative complexity consumes physician and staff time, delays care, and adds financial pressure on independent practices.

In urology, prior authorization can delay diagnostic testing, prostate cancer imaging, procedures, and treatment for patients with cancer, urinary obstruction, kidney stones, and other conditions. Repeated submissions and appeals divert staff from patient care and can delay clinically necessary services.

LUGPA’s goal: Prior authorization and other utilization-management tools should promote appropriate care—not create unnecessary barriers to it.


5. Promote Fair Competition and Meaningful 340B Reform

LUGPA supports a 340B program that serves its intended safety-net purpose while promoting transparency, accountability, program integrity, and fair competition.

LUGPA will advocate for reforms that:

  • Require consistent public reporting of 340B program participation, contract pharmacy arrangements, and the use of program-generated savings, while protecting confidential patient and commercially sensitive information.
  • Strengthen oversight of eligibility, duplicate discounts, and compliance with program requirements.
  • Evaluate how 340B participation and associated payment policies affect hospital acquisition of physician practices and competition between hospital-owned and independent providers.
  • Support physician-led governance and accountability while preserving access to capital and management support that help independent practices remain viable.
  • Promote physician-led clinical governance, transparent ownership and management arrangements, and accountability for harmful conduct without broadly penalizing legitimate practice models.
  • Preserve appropriate access to capital, administrative infrastructure, and management expertise that can help independent practices invest in technology, recruit clinicians, and remain viable.

LUGPA will also continue engaging on broader policies that affect competition between independent physician practices and larger health systems.

Why it matters: Payment and drug programs should support patient access and safety-net care without creating incentives that make it increasingly difficult for independent physicians to compete. Policies governing practice ownership and management should promote accountability without unnecessarily limiting the resources and support physicians need to maintain viable independent practices.

Independent urology practices compete with health systems that may benefit from different reimbursement arrangements and access to capital. Policy should address demonstrated abuses and conflicts of interest without creating additional barriers for independent practices seeking legitimate investment or management support. Similarly, 340B reforms should improve accountability and protect the program’s safety-net purpose without creating incentives that accelerate consolidation.

LUGPA’s goal: Preserve the legitimate purpose of 340B while improving accountability, protecting program integrity, and reducing policies that drive consolidation or undermine independent physician practices.


6. Advance Evidence-Based Innovation and the Future of Urology

Independent practices need the ability to adopt new technologies, diagnostics, and care models without being disadvantaged by outdated payment or coverage policies.

LUGPA will advocate for policies that:

  • Establish timely, transparent coverage and payment pathways for evidence-based urologic diagnostics, including molecular and biomarker tests that can inform cancer risk assessment and treatment decisions.
  • Ensure that Medicare and commercial payers periodically reassess coverage policies for emerging urologic treatments and technologies as clinical evidence evolves.
  • Support appropriate payment for new procedures, technologies, and physician services when existing codes or payment methodologies do not adequately reflect the resources required to deliver them.
  • Promote responsible adoption of artificial intelligence and other digital tools while maintaining physician oversight, patient privacy, and clinical accountability.

LUGPA will also continue working to ensure emerging technologies and procedures are evaluated based on current clinical evidence rather than outdated coverage assumptions.

Why it matters: Innovation can improve diagnosis, treatment, efficiency, and outcomes, but independent practices need payment, coverage, and regulatory policies that allow them to adopt these tools.

Advances in prostate cancer diagnostics, molecular testing, and radiologic therapy are changing how urologic conditions are diagnosed and treated. Independent practices need timely coverage decisions and appropriate reimbursement to offer these advances without being disadvantaged by outdated payment systems or coverage policies.

LUGPA’s goal: Ensure independent urologists can participate in—and help shape—the next generation of specialty care.


LUGPA’s 2027 Legislative Message

Independent urology is an essential part of a competitive, patient-centered health-care system.

LUGPA will work with Congress, the Administration, CMS, state policymakers, health plans, and other stakeholders to advance policies that:

  • Establish predictable Medicare physician payment updates tied to practice costs.
  • Reduce payment incentives that encourage unnecessary hospital acquisition of independent practices.
  • Protect access to physician-administered therapies and evidence-based urologic innovations.
  • Standardize prior authorization and establish meaningful patient-access protections.
  • Improve 340B transparency and accountability while opposing policies that unnecessarily restrict independent practice ownership and management models.
  • Ensure that coverage and payment policies reflect the clinical evidence and costs of delivering modern urologic care.

The goal is simple: Ensure independent urologists can continue to practice, innovate, and provide high-quality specialty care to the patients and communities they serve.